SRPT
Price
$14.07
Change
-$7.90 (-35.96%)
Updated
Jul 18, 04:59 PM (EDT)
Capitalization
2.16B
12 days until earnings call
XNCR
Price
$8.96
Change
-$0.11 (-1.21%)
Updated
Jul 18, 04:59 PM (EDT)
Capitalization
645.52M
12 days until earnings call
Interact to see
Advertisement

SRPT vs XNCR

Header iconSRPT vs XNCR Comparison
Open Charts SRPT vs XNCRBanner chart's image
Sarepta Therapeutics
Price$14.07
Change-$7.90 (-35.96%)
Volume$360.18K
Capitalization2.16B
Xencor
Price$8.96
Change-$0.11 (-1.21%)
Volume$13.04K
Capitalization645.52M
SRPT vs XNCR Comparison Chart in %
Loading...
SRPT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XNCR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
SRPT vs. XNCR commentary
Jul 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SRPT is a Hold and XNCR is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 19, 2025
Stock price -- (SRPT: $21.97 vs. XNCR: $9.07)
Brand notoriety: SRPT: Notable vs. XNCR: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: SRPT: 366% vs. XNCR: 52%
Market capitalization -- SRPT: $2.16B vs. XNCR: $645.52M
SRPT [@Biotechnology] is valued at $2.16B. XNCR’s [@Biotechnology] market capitalization is $645.52M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.62B to $0. The average market capitalization across the [@Biotechnology] industry is $2.46B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SRPT’s FA Score shows that 0 FA rating(s) are green whileXNCR’s FA Score has 1 green FA rating(s).

  • SRPT’s FA Score: 0 green, 5 red.
  • XNCR’s FA Score: 1 green, 4 red.
According to our system of comparison, XNCR is a better buy in the long-term than SRPT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SRPT’s TA Score shows that 4 TA indicator(s) are bullish while XNCR’s TA Score has 5 bullish TA indicator(s).

  • SRPT’s TA Score: 4 bullish, 4 bearish.
  • XNCR’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, XNCR is a better buy in the short-term than SRPT.

Price Growth

SRPT (@Biotechnology) experienced а +15.24% price change this week, while XNCR (@Biotechnology) price change was -2.26% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.49%. For the same industry, the average monthly price growth was +13.01%, and the average quarterly price growth was +34.43%.

Reported Earning Dates

SRPT is expected to report earnings on Oct 29, 2025.

XNCR is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Biotechnology (+2.49% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SRPT($2.16B) has a higher market cap than XNCR($646M). XNCR YTD gains are higher at: -60.531 vs. SRPT (-81.931). SRPT has higher annual earnings (EBITDA): -106.51M vs. XNCR (-161.68M). SRPT has more cash in the bank: 523M vs. XNCR (470M). XNCR has less debt than SRPT: XNCR (67.8M) vs SRPT (1.34B). SRPT has higher revenues than XNCR: SRPT (2.23B) vs XNCR (127M).
SRPTXNCRSRPT / XNCR
Capitalization2.16B646M334%
EBITDA-106.51M-161.68M66%
Gain YTD-81.931-60.531135%
P/E Ratio27.21N/A-
Revenue2.23B127M1,758%
Total Cash523M470M111%
Total Debt1.34B67.8M1,982%
FUNDAMENTALS RATINGS
SRPT vs XNCR: Fundamental Ratings
SRPT
XNCR
OUTLOOK RATING
1..100
35
VALUATION
overvalued / fair valued / undervalued
1..100
62
Fair valued
78
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9597
PRICE GROWTH RATING
1..100
9888
P/E GROWTH RATING
1..100
1004
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SRPT's Valuation (62) in the Biotechnology industry is in the same range as XNCR (78). This means that SRPT’s stock grew similarly to XNCR’s over the last 12 months.

SRPT's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as XNCR (100). This means that SRPT’s stock grew similarly to XNCR’s over the last 12 months.

SRPT's SMR Rating (95) in the Biotechnology industry is in the same range as XNCR (97). This means that SRPT’s stock grew similarly to XNCR’s over the last 12 months.

XNCR's Price Growth Rating (88) in the Biotechnology industry is in the same range as SRPT (98). This means that XNCR’s stock grew similarly to SRPT’s over the last 12 months.

XNCR's P/E Growth Rating (4) in the Biotechnology industry is significantly better than the same rating for SRPT (100). This means that XNCR’s stock grew significantly faster than SRPT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
SRPTXNCR
RSI
ODDS (%)
Bullish Trend 2 days ago
76%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
80%
Momentum
ODDS (%)
Bullish Trend 2 days ago
69%
Bullish Trend 2 days ago
65%
MACD
ODDS (%)
Bullish Trend 2 days ago
66%
Bullish Trend 2 days ago
68%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
73%
Bearish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
72%
Declines
ODDS (%)
Bearish Trend 8 days ago
78%
Bearish Trend 8 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
74%
Bearish Trend 2 days ago
79%
Aroon
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
SRPT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XNCR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MIGBX33.13N/A
N/A
MFS Massachusetts Inv Gr Stk B
FCBSX34.13N/A
N/A
Franklin Mutual U.S. Mid Cap Value C
FRRSX15.45N/A
N/A
Franklin Real Estate Securities C
MWEBX40.68N/A
N/A
MFS Global Equity B
NGJCX18.73N/A
N/A
Nuveen Global Real Estate Securities C